Movement Alert|Moody's Rises 3.1% in Regular Trading, Q2 Earnings Significantly Beat Expectations with Multiple Analyst Target Price Upgrades

Market Focus07-27

On July 27, Moody's rose 3.1% in regular trading, trading at $486.08/share, with turnover of $59.19 million.

The move follows Moody's second-quarter earnings release that significantly exceeded market expectations, coupled with a wave of analyst target price upgrades. Q2 adjusted EPS came in at $4.68, well above the consensus estimate of $4.24 and up 31% year-over-year. Revenue reached $2.19 billion versus the $2.09 billion expected, representing 15% growth. The company also raised its full-year adjusted EPS guidance to $16.50-$17.00 and expanded its share buyback program to $3 billion.

Following the results, multiple institutions raised their price targets: Baird to $572, Barclays to $575, Evercore ISI to $588, Goldman Sachs to $557, and Autonomous Research to $598. The current analyst consensus target stands at $555.55 with an overweight rating. Morgan Stanley highlighted robust bond issuance trends, AI and data-center financing, and M&A recovery as key tailwinds for ratings agencies.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment